Bajaj Healthcare Ltd (BAJAJHCARE) AI Stock Analysis

• Market Cap: ₹14.64B
• Dividend Yield: 0.22%
• Average Volume (3M): 23.28K
• Price to Earnings (P/E): 32.3
• Beta (1Y): 0.93
• Revenue Growth: 17.50%
• EPS Growth: N/A
• Country: IN
• Employees: 1,049
• Sector: Healthcare
• Sector Strength: 41
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 3.75
• Shares Outstanding: 31,583,252
• 10 Day Avg. Volume: 15,102
• 30 Day Avg. Volume: 23,276
• PEG Ratio: -0.38
• Price to Book (P/B): 4.64
• Price to Sales (P/S): 3.98
• P/FCF Ratio: -124.79
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹503.00
• Price Target Upside: 8.53% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 52 Neutral
• Price Target: ₹503.00 ▲(8.53% Upside)

The overall stock score is driven by moderate financial performance with significant leverage and liquidity concerns. The technical analysis indicates weak momentum, and the valuation suggests the stock may be overpriced. Lack of earnings call data and corporate events further limits positive assessment.

Bajaj Healthcare Ltd Business Overview & Revenue Model

Company Description

Bajaj Healthcare Ltd (BAJAJHCARE) is an Indian pharmaceutical company engaged in the manufacturing and marketing of a wide range of pharmaceutical products. The company operates in the sectors of active pharmaceutical ingredients (APIs), intermediates, and formulations. Bajaj Healthcare's core products include a variety of pharmaceutical compounds used in the treatment of multiple therapeutic areas, including analgesics, anti-infectives, and cardiovascular drugs.

How the Company Makes Money

Bajaj Healthcare Ltd generates revenue primarily through the production and sale of active pharmaceutical ingredients (APIs) and finished dosage formulations. The company supplies these products to domestic and international pharmaceutical companies, contributing to its revenue streams. Additionally, Bajaj Healthcare benefits from strategic partnerships and collaborations that enhance its product offerings and market reach. The company's earnings are driven by its ability to develop cost-effective and high-quality pharmaceutical products that meet industry standards and regulatory requirements.

Bajaj Healthcare Ltd Financial Statement Overview

Summary

Bajaj Healthcare Ltd shows moderate financial performance with fluctuating revenue growth and improved net profit margin. However, high leverage, inconsistent return on equity, and negative free cash flow pose significant financial risks.

Income Statement

The company's revenue has shown fluctuating growth over recent years, with a decline in 2025 compared to 2023. Gross profit margin and EBIT margin have decreased, indicating potential cost management issues. However, the net profit margin improved in 2025, recovering from negative profitability in 2024. Overall, the income statement reflects moderate profitability with some volatility in revenue growth.

Balance Sheet

The debt-to-equity ratio is relatively high, indicating significant leverage which could pose financial risks. Return on equity has been inconsistent, reflecting variability in net income. The equity ratio has improved, indicating a healthier balance between debt and assets, but the overall leverage remains a concern.

Cash Flow

Cash flow from operations has been inconsistent, with negative free cash flow in recent years. The operating cash flow to net income ratio is concerning, indicating challenges in converting profits into cash. Financing cash flows have been positive, suggesting reliance on external financing. Overall, cash flow management presents a potential area of concern.

Breakdown	TTM	Dec 2025	Dec 2023	Dec 2023	Dec 2021	Dec 2020
Income Statement
Total Revenue	5.22B	5.43B	6.73B	4.73B	6.79B	3.59B
Gross Profit	2.09B	1.71B	1.83B	2.16B	1.84B	948.25M
EBITDA	538.06M	1.02B	1.13B	406.24M	1.22B	554.87M
Net Income	-16.07M	394.95M	430.24M	-837.93M	713.86M	252.37M
Balance Sheet
Total Assets	0.00	8.33B	9.01B	7.65B	7.21B	3.26B
Cash, Cash Equivalents and Short-Term Investments	228.40M	44.51M	223.20M	29.29M	19.75M	41.58M
Total Debt	0.00	2.23B	4.15B	3.33B	2.57B	909.26M
Total Liabilities	-4.46B	3.67B	5.34B	4.87B	3.93B	1.74B
Stockholders Equity	4.46B	4.66B	3.68B	2.78B	3.28B	1.52B
Cash Flow
Free Cash Flow	0.00	-173.16M	-1.46B	620.08M	-786.19M	-21.15M
Operating Cash Flow	0.00	-57.78M	-223.24M	922.94M	6.86M	205.75M
Investing Cash Flow	0.00	-153.21M	-934.27M	-112.45M	-747.98M	-275.60M
Financing Cash Flow	0.00	215.28M	1.31B	-547.20M	618.46M	32.82M

Bajaj Healthcare Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 463.45
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BAJAJHCARE, the sentiment is Negative. The current price of 463.45 is below the 20-day moving average (MA) of 493.26, below the 50-day MA of 504.10, and below the 200-day MA of 538.78, indicating a bearish trend. The MACD of -15.66 indicates Positive momentum. The RSI at 39.32 is Neutral, neither overbought nor oversold. The STOCH value of 19.43 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:BAJAJHCARE.

Bajaj Healthcare Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
JAGSNPHARM	74 Outperform	₹16.48B	27.07		0.79%	34.72%	196.57%
HESTERBIO	68 Neutral	₹16.48B	43.83		0.36%	4.68%	94.22%
BLISSGVS	67 Neutral	₹18.43B	17.25		0.29%	4.93%	29.92%
SYNCOMF	62 Neutral	₹16.64B	30.30		―	70.43%	92.33%
THEMISMED	56 Neutral	₹9.78B	33.15		0.45%	-6.86%	-118.14%
BAJAJHCARE	52 Neutral	₹14.64B	32.28		0.22%	17.50%	―
Sector *	51 Neutral	kr6.00B	8.78	-28.70%	2.24%	51.61%	19.20%

Bajaj Healthcare Ltd Corporate Events

Bajaj Healthcare Releases Q1 2025 Financial Results

Bajaj Healthcare Limited has published its un-audited financial results for the quarter ending June 30, 2025, in compliance with SEBI regulations. The results, which were released in major newspapers, indicate the company’s ongoing financial performance and are part of its regulatory disclosure obligations, potentially impacting stakeholders’ insights into its operational health.

Bajaj Healthcare Reports Strong Q1 FY26 Results with Significant Profit Growth

Bajaj Healthcare Limited reported a strong performance for the first quarter of FY26, with a 12.5% increase in revenue to ₹1,488.4 million and a significant 66% growth in profit after tax to ₹118.3 million. The company achieved this despite challenging pricing conditions, by improving its product mix and leveraging operating efficiencies. The API export segment experienced a remarkable 68.4% year-on-year growth, driven by demand in regulated markets, while the formulations segment grew by 41.1% due to enhanced market penetration and strategic partnerships. The company is strategically realigning its portfolio towards value-added exports and differentiated molecules to sustain growth and profitability.